Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 854,981 |
|
|||||
| News | - | ||||||
| Day High | 9.58 | Low High |
|||||
| Day Low | 9.05 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Neumora Therapeutics Inc | NMRA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.34 | 3.71% | 9.51 | 16:26:22 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 9.39 | 9.05 | 9.58 | 9.51 | 9.17 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 9,029 | 854,981 | $ 9.30 | $ 7,954,432 | - | 8.82 - 21.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:19 | 3 | $ 9.51 | USD |
Neumora Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.51B | 158.89M | - | 0 | -235.93M | -1.48 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Neumora Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NMRA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.65 | 9.805 | 8.95 | 9.43 | 454,685 | -0.14 | -1.45% |
| 1 Month | 9.49 | 10.15 | 8.84 | 9.41 | 483,570 | 0.02 | 0.21% |
| 3 Months | 17.11 | 21.00 | 8.82 | 12.36 | 667,159 | -7.60 | -44.42% |
| 6 Months | 11.83 | 21.00 | 8.82 | 13.44 | 466,004 | -2.32 | -19.61% |
| 1 Year | 16.50 | 21.00 | 8.82 | 13.07 | 433,312 | -6.99 | -42.36% |
| 3 Years | 16.50 | 21.00 | 8.82 | 13.07 | 433,312 | -6.99 | -42.36% |
| 5 Years | 16.50 | 21.00 | 8.82 | 13.07 | 433,312 | -6.99 | -42.36% |
Neumora Therapeutics Description
| Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. |
